Bioanalysis
Current Strategies for Using Commercial LBA Kit in Regulated Bioanalysis
Four Key Steps to Optimizing a Large Molecule Bioanalytical Program
Biologics are large, complex molecules that can undergo structural changes during the manufacturing process, storage, or administration to patients. This means bioanalysis of biologics is a critical aspect of the drug development process, and one that requires sensitivity, specificity, and selectivity.
Microsampling Podcast - Breakthrough Novel Application for the Analysis of ASOs
Coupling Hybridization LC-MS Workflows with Microsampling for the Analysis of Antisense Oligonucleotides
Join Altasciences’ scientific experts as they discuss novel LC-MS-based strategies and workflows for the quantitative bioanalysis of oligonucleotide therapeutics (ASO) via dried blood microsampling.
Discover how this breakthrough novel application can:
- be applied to nonclinical studies
- facilitate remote sample collection for patient-centric trials
- eliminate the tedious and often error-prone approach that occurs when using liquid-based capillary microsampling
Speak with one of our experts to learn more about our service offering.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Have five minutes? Take a look at these:
- Webpages:
- Podcast: Microsampling: When Small Steps Lead to Big Outcomes
- eBook: Developments for the Analysis of Antisense Oligonucleotides
- The Altascientist: Microsampling in Drug Development
- Webinar: Patient Centricity and the Evolving Role of Microsampling
Hybridization LC-MS/MS Workflow to Quantify an siRNA Drug Candidate in Plasma, CSF, and Tissues
Overcome Matrix Shortage and Non-specific Binding Issues
Surrogate Cerebrospinal Fluid Method for ASO Quantitation
In this presentation, we identify a suitable surrogate matrix to overcome issues regarding the shortage of nonhuman primate matrices, and susceptibility to non-specific binding (inherent in the analysis of oligonucleotides), including the use of artificial cerebrospinal fluid.
Listen to the presentation!
You may also be interested in the following:
- Webpages:
- eBook: Bioanalytical Developments for the Analysis of ASOs
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Accelerate Your Data with Our Co-located Clinic and Lab
Ensuring Chain of Custody from Clinic to Lab
Did you know that our Canadian clinical facility is only a 15-minute drive from our bioanalytical facility?
This two-minute video provides an overview of our workflows, optimized to ensure timely collection, processing, transport, and rapid analysis of your samples for expedited go/no-go decision-making. Altasciences’ highly trained clinical staff and lab analysts understand the time-sensitive nature of your projects. Real-time access to essential data is our top priority.
Speak with one of our experts to learn more about our solution and how we can support your program.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Have five minutes? Take a look at these:
Benefits of Increasing Automation in the Lab
In this webinar, learn about the extent of automation within bioanalysis in today’s landscape, the practicality of automated technologies for extraction methods and ligand binding assays, and future projections for bioanalytical automation.
Speak with an expert about your research needs.
You may also be interested in the following:
- Webpage: Bioanalytical Platforms
- The Altascientist: The Evolution and Advancement of LC-MS in Drug Development
The Altascientist—Scientific Journal on Recent LC-MS/MS Innovations (includes six case studies!)
In this issue of The Altascientist, we cover the innovative progress we have recently seen in mass spectrometry, and how the advancements of science and technology can help you achieve critical milestones in your early phase drug development study or program.
In this issue you will explore:
- The case for stable isotope labelled internal standards for LC-MS quantitation
- Recent innovations in mass spectrometry
- Six case studies
You may also be interested in the following:
WRIB 2022 Poster Presentation: Development of Surrogate CSF for Quantitative Analysis of ASOs by Hybridization LC-MS/MS
Webinars:
- Panel Discussion—Automation in the Bioanalytical Laboratory
- Selectivity, Selectivity, Selectivity—A New Dimension by Differential Mobility Spectrometry
Podcast: Microsampling: When Small Steps Lead to Big Outcomes